Cardiorenal effects of therapies for type 2 diabetes and obesity
The British Journal of Cardiology
OCTOBER 8, 2024
Sodium-glucose cotransporter type 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering and weight-lowering agents used in the management of type 2 diabetes mellitus and obesity.
Let's personalize your content